SlideShare ist ein Scribd-Unternehmen logo
1 von 22
ONCOLOGY AT THE PERIPHERY 
Matilda.K.Ongóndi 
Physician: Kenyatta National Hospital
 300 bed capacity. 
 Started giving chemo 
2011 prior few cases 
mostly paeds.
Demographics 
 31 patients. 
 M:F ratio…...1.2:1 (14 females, 17males) 
gender 
male 
female
14 
12 
10 
8 
6 
4 
2 
0 
Frequency per age group 
0-10 11 to 20 21-30 31-40 41-50 51-60 61-70 >71yrs 
No. 
Age group 
Mean age: 42.6yrs with range 4-89yrs
Diagnosis n stage 
Kaposis Sarcoma 12 low=high 
risk 
Non-hodgkins lymphoma 
(DLBCL 3, Burkitts 4, Follicular lymphoma1, T 
cell lymphoblastic lymphoma 1) 
10 
*suspected 
Stage I- 
1,II-2, IV- 
7 
Hodgkins Lymphoma 3 IV-2, II-1 
Multiple myeloma 2 III 
Esophageal cancer 1 IV 
CLL 1 II 
Breast Cancer 1 II
Requirement to make a diagnosis 
Lymph node biopsy 8 
Punch biopsy 6 
Interventional radiologist 1 
BMA 2 
Sx intervention 14 
Core needle biopsy (axillary mass biopsy, liver mass), nasal 
mass, supraglottic mass, tonsillar mass, gingival mass, uvula 
mass, laparatomy-intra-abdominal biopsy, endoscopy, foot bx, 
colonoscopy, laminectomy
Time to diagnosis 
350 
300 
250 
200 
150 
100 
50 
0 
Tx as 
TB,default 
Conflicting biopsy 
reports 
a b c d e f g h i j k l m n o p q r s t u v w x y 
No. of days 
Mean time: 43 days with range 3 to 318 days. 
(data from 26 patients)
Time to initiation of chemo: 20days 
(range: 2- 70days) 
23 patients..data available. 
Pt. counselled on diagnosis and chemotherapy as 
well as cost; reduced time. 
Team work…multi-disciplinary consult (direct 
communication).
Co-morbidities 
1 KS all had HIV except 2 African 
endemic KS 
2 Diabetes Mellitus 
3 Sputum +ve TB (HIV negative): HL* 
4 Systolic hypertension 
5 COPD 
6 Hep B/HIV co-infection with BL
Complications @ presentation 
1 Superior Vena Cava syndrome 
** chylothorax 
2 Upper airway obstruction with dysphagia 
3 Paraplegia 
4 Post-obstructive pneumonia 
5 Dry gangrene and cryoglobulinaemia 
6 DVT
Complication tx associated 
1 Leucopenia 
2 Tumour lysis syndrome (worsening 
hypoxia) 
3 Post chemo-port insertion: clot in SVC
Mortality: 25% (7 patients) 
Reason for mortality: 
1) sepsis (2) 
2) treatment failure (2) 
3) Extensive d’se (1..primary respiratory failure, 
?castelman) 
4) Uncertain (1-prior chemo)
Lost to follow up: 7 (financial reasons) 
Evaluation of patients adherence to chemotherapy for breast cancer. 
Adewale O Adisa, Omkayede O, et al 
African Journal of health sciences Vol 15, no 1-2, Jan –March 20007;p22-27 
10yr period (Jan 1993 to Dec 2002), 225 females and 6 males. 
56% stage 4 at presentation, non-adherence was 80.9% (73% not 
seen again) 
Reasons: financial, thought well enough, fearful of sx, unable to 
bear side effect. 
1
Compliance with chemotherapy in childhood leukaemia 
in Africa. 
Mac Dougall LG, Wilson TD, Cohn R, Shuenyane EN 
S. Africa Medical journal 1989 May 20; 75 (10): 481-4 
Compliance of chemotherapy in childhood leukaemia 
good due to parental fear of disease. 
15 blacks, 30 white children 
53% blacks attended clinic on appointment day. 
<50% understood nature of child’s illness. 
White parents reported toxic effects more frequently. 
3
HOW 
One man /woman 
show: identify 
patients, not 
sustainable. 
Interested colleagues: 
nurse…assist give drugs 
More Interested colleagues: 
nurses: Mix drugs: VB…KS, review by CO no issue, 
give drug. Be informed. 
Other chemo: mix then they would fix it after 
fluids: inform me when chemo was done. 
Pharmacist (Dr) trained in KNH : mix chemo 
Later pharm techs.
3 copies: 
1. file..paper 
chart. 
2. Patient. 
3. File in 
pharmacy
Interesting!!!!
Lessons learnt 
Challenges: late presentation pt and clinician factors, 
working up patients and financial constraints 
influencing time lines, cost of meds. 
Cannot work alone (success due to team 
support…institution and colleagues). 
Support from hemato-oncologists (phone 
consultation). 
Pt understanding condition and need f/u.
Conclusion 
Reality- increasing number of patients, more 
advanced dse, misdiagnosis/late diagnosis in the 
face of financial constraints limiting accessibility. 
Cannot have oncologist everywhere! 
Presentation shows its possible to give simple 
chemo regimens in periphery facilities with good 
support.
Acknowledgement 
• Tenwek Hospital: mx and staff 
Nurses: Dennis, Caroline ,Linner Rotich, Phylis Siele 
Pharmacy: Dr Langat,Isaiah, Wesley 
MO: Dr Masese and Sirera 
• Dr Sylvester. Kimutai …data collection and review 
• Dr MD Maina, Dr Ann Waweru: phone consults 
• KESHO secretariat/ Novartis (sponsorship) 
• Colleagues in Hemato-Oncology at KNH/UON
Asante Sana

Weitere ähnliche Inhalte

Was ist angesagt?

Graft-vs.-Host Disease and Umbilical Cord Transplantation
Graft-vs.-Host Disease and Umbilical Cord TransplantationGraft-vs.-Host Disease and Umbilical Cord Transplantation
Graft-vs.-Host Disease and Umbilical Cord Transplantation
cordbloodsymposium
 
19 chronic%20 gvhd[1]
19 chronic%20 gvhd[1]19 chronic%20 gvhd[1]
19 chronic%20 gvhd[1]
amc_editorial
 
HIV Primary Care
HIV Primary CareHIV Primary Care
HIV Primary Care
tjsiddiqui
 

Was ist angesagt? (18)

Actualización en la etiología, clasificación y manejo de las glomerulopatías.pdf
Actualización en la etiología, clasificación y manejo de las glomerulopatías.pdfActualización en la etiología, clasificación y manejo de las glomerulopatías.pdf
Actualización en la etiología, clasificación y manejo de las glomerulopatías.pdf
 
Gvhd
GvhdGvhd
Gvhd
 
Graft-vs.-Host Disease and Umbilical Cord Transplantation
Graft-vs.-Host Disease and Umbilical Cord TransplantationGraft-vs.-Host Disease and Umbilical Cord Transplantation
Graft-vs.-Host Disease and Umbilical Cord Transplantation
 
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients. Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients.
 
SARS CoV-2 Up to Date
SARS CoV-2 Up to DateSARS CoV-2 Up to Date
SARS CoV-2 Up to Date
 
Zoulim article cshperspectmed-hep-a021501-proof seen d dfz copie
Zoulim article  cshperspectmed-hep-a021501-proof seen d dfz copieZoulim article  cshperspectmed-hep-a021501-proof seen d dfz copie
Zoulim article cshperspectmed-hep-a021501-proof seen d dfz copie
 
Role of tips in liver disease
Role of tips in liver diseaseRole of tips in liver disease
Role of tips in liver disease
 
Acute pancreatitis
Acute pancreatitisAcute pancreatitis
Acute pancreatitis
 
Graft versus host disease
Graft versus host diseaseGraft versus host disease
Graft versus host disease
 
Graft Versus Host Disease
Graft Versus Host DiseaseGraft Versus Host Disease
Graft Versus Host Disease
 
Covid-19 and Kidey Transplantation
Covid-19 and Kidey TransplantationCovid-19 and Kidey Transplantation
Covid-19 and Kidey Transplantation
 
Hiv associted dvt
Hiv associted dvtHiv associted dvt
Hiv associted dvt
 
19 chronic%20 gvhd[1]
19 chronic%20 gvhd[1]19 chronic%20 gvhd[1]
19 chronic%20 gvhd[1]
 
Noon conference tb 7-31-18
Noon conference tb 7-31-18Noon conference tb 7-31-18
Noon conference tb 7-31-18
 
150th publication jfmpc- 3rd name
150th publication  jfmpc- 3rd name150th publication  jfmpc- 3rd name
150th publication jfmpc- 3rd name
 
American Journal of Genetics & Genomics
American Journal of Genetics & GenomicsAmerican Journal of Genetics & Genomics
American Journal of Genetics & Genomics
 
American Journal of Genetics & Genomics
American Journal of Genetics & GenomicsAmerican Journal of Genetics & Genomics
American Journal of Genetics & Genomics
 
HIV Primary Care
HIV Primary CareHIV Primary Care
HIV Primary Care
 

Andere mochten auch

Does nhif improve survival of wilms tumor kenya by fatma abdalla
Does nhif improve survival of wilms tumor kenya by fatma abdallaDoes nhif improve survival of wilms tumor kenya by fatma abdalla
Does nhif improve survival of wilms tumor kenya by fatma abdalla
Kesho Conference
 
Palliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruPalliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weru
Kesho Conference
 
Ethnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdallaEthnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdalla
Kesho Conference
 
Synthesis of thienyl appended porphyrins for cancer treatment by edith amuhaya
Synthesis of thienyl appended porphyrins for cancer treatment by edith amuhayaSynthesis of thienyl appended porphyrins for cancer treatment by edith amuhaya
Synthesis of thienyl appended porphyrins for cancer treatment by edith amuhaya
Kesho Conference
 
Current and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutalaCurrent and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutala
Kesho Conference
 
2 d vs. 3d external beam planning in cervical cancer by nelson mandela
2 d vs. 3d external beam planning in cervical cancer by nelson mandela2 d vs. 3d external beam planning in cervical cancer by nelson mandela
2 d vs. 3d external beam planning in cervical cancer by nelson mandela
Kesho Conference
 
Sentinel lymph node concept in early breast cancer by prof. r. wasike
Sentinel lymph node concept in early breast cancer by prof. r. wasikeSentinel lymph node concept in early breast cancer by prof. r. wasike
Sentinel lymph node concept in early breast cancer by prof. r. wasike
Kesho Conference
 

Andere mochten auch (19)

Does nhif improve survival of wilms tumor kenya by fatma abdalla
Does nhif improve survival of wilms tumor kenya by fatma abdallaDoes nhif improve survival of wilms tumor kenya by fatma abdalla
Does nhif improve survival of wilms tumor kenya by fatma abdalla
 
Oncology at the periphery by matilda ong'ondi
Oncology at the periphery by matilda ong'ondiOncology at the periphery by matilda ong'ondi
Oncology at the periphery by matilda ong'ondi
 
Earlier detection of cancer in sudan by kamal hamed
Earlier detection of cancer in sudan by kamal hamedEarlier detection of cancer in sudan by kamal hamed
Earlier detection of cancer in sudan by kamal hamed
 
Texas cancer centre by jipsy contractors
Texas cancer centre by  jipsy contractorsTexas cancer centre by  jipsy contractors
Texas cancer centre by jipsy contractors
 
Palliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruPalliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weru
 
Ethnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdallaEthnic disparities in wilms tumor by fatma abdalla
Ethnic disparities in wilms tumor by fatma abdalla
 
Global oncology by david miller
Global oncology by david millerGlobal oncology by david miller
Global oncology by david miller
 
Opportunities in interventional oncology by henry wanga
Opportunities in interventional oncology by henry wangaOpportunities in interventional oncology by henry wanga
Opportunities in interventional oncology by henry wanga
 
Setting up a cancer centre by joshua ndoli
Setting up a cancer centre by joshua ndoliSetting up a cancer centre by joshua ndoli
Setting up a cancer centre by joshua ndoli
 
Spearheading cancer awareness by benda kithaka
Spearheading cancer awareness by benda kithakaSpearheading cancer awareness by benda kithaka
Spearheading cancer awareness by benda kithaka
 
Overview of palliative care by esther muinga
Overview of palliative care by esther muingaOverview of palliative care by esther muinga
Overview of palliative care by esther muinga
 
Synthesis of thienyl appended porphyrins for cancer treatment by edith amuhaya
Synthesis of thienyl appended porphyrins for cancer treatment by edith amuhayaSynthesis of thienyl appended porphyrins for cancer treatment by edith amuhaya
Synthesis of thienyl appended porphyrins for cancer treatment by edith amuhaya
 
Current and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutalaCurrent and emerging partnerships in imaging and radiotherapy by musila mutala
Current and emerging partnerships in imaging and radiotherapy by musila mutala
 
Optimising pain management by esther munyoro
Optimising pain management by esther munyoroOptimising pain management by esther munyoro
Optimising pain management by esther munyoro
 
Iron metabolism and management of iron overload by m.d. maina
Iron metabolism and management of iron overload by m.d. mainaIron metabolism and management of iron overload by m.d. maina
Iron metabolism and management of iron overload by m.d. maina
 
Breast cancer 2014 by sd moodley
Breast cancer 2014 by sd moodleyBreast cancer 2014 by sd moodley
Breast cancer 2014 by sd moodley
 
2 d vs. 3d external beam planning in cervical cancer by nelson mandela
2 d vs. 3d external beam planning in cervical cancer by nelson mandela2 d vs. 3d external beam planning in cervical cancer by nelson mandela
2 d vs. 3d external beam planning in cervical cancer by nelson mandela
 
Use of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodoUse of flow cytometric immunophenotyping by teresa lotodo
Use of flow cytometric immunophenotyping by teresa lotodo
 
Sentinel lymph node concept in early breast cancer by prof. r. wasike
Sentinel lymph node concept in early breast cancer by prof. r. wasikeSentinel lymph node concept in early breast cancer by prof. r. wasike
Sentinel lymph node concept in early breast cancer by prof. r. wasike
 

Ähnlich wie Oncology at the periphery by matilda ong'ondi

Hodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S LymphomaHodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S Lymphoma
fondas vakalis
 
ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)
ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)
ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)
KETAN VAGHOLKAR
 
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor RiskFrancesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
incucai_isodp
 
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
MerqurioEditore_redazione
 
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
MerqurioEditore_redazione
 

Ähnlich wie Oncology at the periphery by matilda ong'ondi (20)

Case 1 & 2
Case 1 & 2Case 1 & 2
Case 1 & 2
 
Hodgkin lymphoma
Hodgkin lymphomaHodgkin lymphoma
Hodgkin lymphoma
 
Multiple Hepatic and Osseous Focal Lesions without Splenomegaly and/or Lymph ...
Multiple Hepatic and Osseous Focal Lesions without Splenomegaly and/or Lymph ...Multiple Hepatic and Osseous Focal Lesions without Splenomegaly and/or Lymph ...
Multiple Hepatic and Osseous Focal Lesions without Splenomegaly and/or Lymph ...
 
testicular tumor
testicular tumortesticular tumor
testicular tumor
 
Hodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S LymphomaHodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S Lymphoma
 
Small Bowel Obstruction
Small Bowel ObstructionSmall Bowel Obstruction
Small Bowel Obstruction
 
ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)
ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)
ABDOMINAL TUBERCULOSIS (STUDY OF 50 CASES)
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)
 
38th Publication- JFMPC- 3rd Name.pdf
38th Publication- JFMPC- 3rd Name.pdf38th Publication- JFMPC- 3rd Name.pdf
38th Publication- JFMPC- 3rd Name.pdf
 
Monstering Humans.Ppt 2003
Monstering Humans.Ppt 2003Monstering Humans.Ppt 2003
Monstering Humans.Ppt 2003
 
Burkit’s lymphoma, By Dr Opiro Keneth
Burkit’s  lymphoma, By Dr Opiro KenethBurkit’s  lymphoma, By Dr Opiro Keneth
Burkit’s lymphoma, By Dr Opiro Keneth
 
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor RiskFrancesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
 
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
 
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
 
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
 
Studio italiano su 4187 pazienti
Studio italiano su 4187 pazientiStudio italiano su 4187 pazienti
Studio italiano su 4187 pazienti
 
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
Caratteristiche cliniche e patologiche del carcinoma differenziato della tiro...
 
Risk factors of chronic liver disease amongst patients receiving care in a Ga...
Risk factors of chronic liver disease amongst patients receiving care in a Ga...Risk factors of chronic liver disease amongst patients receiving care in a Ga...
Risk factors of chronic liver disease amongst patients receiving care in a Ga...
 
Hemophagocytic Lymphohistiocytosis - HLH
Hemophagocytic Lymphohistiocytosis - HLHHemophagocytic Lymphohistiocytosis - HLH
Hemophagocytic Lymphohistiocytosis - HLH
 
Hodgkin lymphoma db.pptx
Hodgkin lymphoma db.pptxHodgkin lymphoma db.pptx
Hodgkin lymphoma db.pptx
 

Mehr von Kesho Conference

Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Kesho Conference
 
Opportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidinaOpportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidina
Kesho Conference
 
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushnyEpidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
Kesho Conference
 
Cervical cancer screening and tratment through the private sector by rachel m...
Cervical cancer screening and tratment through the private sector by rachel m...Cervical cancer screening and tratment through the private sector by rachel m...
Cervical cancer screening and tratment through the private sector by rachel m...
Kesho Conference
 
Sickle cell disease registry and prevalence of sickle cell disease in kenya b...
Sickle cell disease registry and prevalence of sickle cell disease in kenya b...Sickle cell disease registry and prevalence of sickle cell disease in kenya b...
Sickle cell disease registry and prevalence of sickle cell disease in kenya b...
Kesho Conference
 

Mehr von Kesho Conference (16)

The making of texas cancer centre by catherine nyongesa
The making of texas cancer centre by catherine nyongesaThe making of texas cancer centre by catherine nyongesa
The making of texas cancer centre by catherine nyongesa
 
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
Study of tenwek esophageal squamous dysplasia prevalence by michael mwachiro ...
 
Stamp out stigma in kenya by vijay narayanan
Stamp out stigma in kenya by vijay narayananStamp out stigma in kenya by vijay narayanan
Stamp out stigma in kenya by vijay narayanan
 
Setting up a cancer centre by catherine nyongesa
Setting up a cancer centre by catherine nyongesaSetting up a cancer centre by catherine nyongesa
Setting up a cancer centre by catherine nyongesa
 
Predictors of imatinib failure in cml by prof. abinya
Predictors of imatinib failure in cml by prof. abinyaPredictors of imatinib failure in cml by prof. abinya
Predictors of imatinib failure in cml by prof. abinya
 
Post operative electron beam therapy for keloids by loreh peter
Post operative electron beam therapy for keloids by loreh peterPost operative electron beam therapy for keloids by loreh peter
Post operative electron beam therapy for keloids by loreh peter
 
Opportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidinaOpportunities and challenges in starting an oncology program by amyn alidina
Opportunities and challenges in starting an oncology program by amyn alidina
 
Joining forces to overcome cancer by izaq odongo
Joining forces to overcome cancer by izaq odongoJoining forces to overcome cancer by izaq odongo
Joining forces to overcome cancer by izaq odongo
 
History of kesho by dr catherine nyongesa
History of kesho by dr catherine nyongesaHistory of kesho by dr catherine nyongesa
History of kesho by dr catherine nyongesa
 
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushnyEpidemiology of cancer in patients seeking palliative care by l.w. cushny
Epidemiology of cancer in patients seeking palliative care by l.w. cushny
 
Electronic portal imaging by rose wekesa
Electronic portal imaging by rose wekesaElectronic portal imaging by rose wekesa
Electronic portal imaging by rose wekesa
 
Creation of a novel cancer & hiv linked registry by jamilla rajab
Creation of a novel cancer & hiv linked registry by jamilla rajabCreation of a novel cancer & hiv linked registry by jamilla rajab
Creation of a novel cancer & hiv linked registry by jamilla rajab
 
Cervical cancer screening and tratment through the private sector by rachel m...
Cervical cancer screening and tratment through the private sector by rachel m...Cervical cancer screening and tratment through the private sector by rachel m...
Cervical cancer screening and tratment through the private sector by rachel m...
 
Acute leukaemias othieno abinya
Acute leukaemias othieno abinyaAcute leukaemias othieno abinya
Acute leukaemias othieno abinya
 
Stemming the medical exodus by alfred odhiambo
Stemming the medical exodus by alfred odhiamboStemming the medical exodus by alfred odhiambo
Stemming the medical exodus by alfred odhiambo
 
Sickle cell disease registry and prevalence of sickle cell disease in kenya b...
Sickle cell disease registry and prevalence of sickle cell disease in kenya b...Sickle cell disease registry and prevalence of sickle cell disease in kenya b...
Sickle cell disease registry and prevalence of sickle cell disease in kenya b...
 

Oncology at the periphery by matilda ong'ondi

  • 1. ONCOLOGY AT THE PERIPHERY Matilda.K.Ongóndi Physician: Kenyatta National Hospital
  • 2.  300 bed capacity.  Started giving chemo 2011 prior few cases mostly paeds.
  • 3. Demographics  31 patients.  M:F ratio…...1.2:1 (14 females, 17males) gender male female
  • 4. 14 12 10 8 6 4 2 0 Frequency per age group 0-10 11 to 20 21-30 31-40 41-50 51-60 61-70 >71yrs No. Age group Mean age: 42.6yrs with range 4-89yrs
  • 5. Diagnosis n stage Kaposis Sarcoma 12 low=high risk Non-hodgkins lymphoma (DLBCL 3, Burkitts 4, Follicular lymphoma1, T cell lymphoblastic lymphoma 1) 10 *suspected Stage I- 1,II-2, IV- 7 Hodgkins Lymphoma 3 IV-2, II-1 Multiple myeloma 2 III Esophageal cancer 1 IV CLL 1 II Breast Cancer 1 II
  • 6. Requirement to make a diagnosis Lymph node biopsy 8 Punch biopsy 6 Interventional radiologist 1 BMA 2 Sx intervention 14 Core needle biopsy (axillary mass biopsy, liver mass), nasal mass, supraglottic mass, tonsillar mass, gingival mass, uvula mass, laparatomy-intra-abdominal biopsy, endoscopy, foot bx, colonoscopy, laminectomy
  • 7. Time to diagnosis 350 300 250 200 150 100 50 0 Tx as TB,default Conflicting biopsy reports a b c d e f g h i j k l m n o p q r s t u v w x y No. of days Mean time: 43 days with range 3 to 318 days. (data from 26 patients)
  • 8. Time to initiation of chemo: 20days (range: 2- 70days) 23 patients..data available. Pt. counselled on diagnosis and chemotherapy as well as cost; reduced time. Team work…multi-disciplinary consult (direct communication).
  • 9. Co-morbidities 1 KS all had HIV except 2 African endemic KS 2 Diabetes Mellitus 3 Sputum +ve TB (HIV negative): HL* 4 Systolic hypertension 5 COPD 6 Hep B/HIV co-infection with BL
  • 10. Complications @ presentation 1 Superior Vena Cava syndrome ** chylothorax 2 Upper airway obstruction with dysphagia 3 Paraplegia 4 Post-obstructive pneumonia 5 Dry gangrene and cryoglobulinaemia 6 DVT
  • 11.
  • 12. Complication tx associated 1 Leucopenia 2 Tumour lysis syndrome (worsening hypoxia) 3 Post chemo-port insertion: clot in SVC
  • 13. Mortality: 25% (7 patients) Reason for mortality: 1) sepsis (2) 2) treatment failure (2) 3) Extensive d’se (1..primary respiratory failure, ?castelman) 4) Uncertain (1-prior chemo)
  • 14. Lost to follow up: 7 (financial reasons) Evaluation of patients adherence to chemotherapy for breast cancer. Adewale O Adisa, Omkayede O, et al African Journal of health sciences Vol 15, no 1-2, Jan –March 20007;p22-27 10yr period (Jan 1993 to Dec 2002), 225 females and 6 males. 56% stage 4 at presentation, non-adherence was 80.9% (73% not seen again) Reasons: financial, thought well enough, fearful of sx, unable to bear side effect. 1
  • 15. Compliance with chemotherapy in childhood leukaemia in Africa. Mac Dougall LG, Wilson TD, Cohn R, Shuenyane EN S. Africa Medical journal 1989 May 20; 75 (10): 481-4 Compliance of chemotherapy in childhood leukaemia good due to parental fear of disease. 15 blacks, 30 white children 53% blacks attended clinic on appointment day. <50% understood nature of child’s illness. White parents reported toxic effects more frequently. 3
  • 16. HOW One man /woman show: identify patients, not sustainable. Interested colleagues: nurse…assist give drugs More Interested colleagues: nurses: Mix drugs: VB…KS, review by CO no issue, give drug. Be informed. Other chemo: mix then they would fix it after fluids: inform me when chemo was done. Pharmacist (Dr) trained in KNH : mix chemo Later pharm techs.
  • 17. 3 copies: 1. file..paper chart. 2. Patient. 3. File in pharmacy
  • 19. Lessons learnt Challenges: late presentation pt and clinician factors, working up patients and financial constraints influencing time lines, cost of meds. Cannot work alone (success due to team support…institution and colleagues). Support from hemato-oncologists (phone consultation). Pt understanding condition and need f/u.
  • 20. Conclusion Reality- increasing number of patients, more advanced dse, misdiagnosis/late diagnosis in the face of financial constraints limiting accessibility. Cannot have oncologist everywhere! Presentation shows its possible to give simple chemo regimens in periphery facilities with good support.
  • 21. Acknowledgement • Tenwek Hospital: mx and staff Nurses: Dennis, Caroline ,Linner Rotich, Phylis Siele Pharmacy: Dr Langat,Isaiah, Wesley MO: Dr Masese and Sirera • Dr Sylvester. Kimutai …data collection and review • Dr MD Maina, Dr Ann Waweru: phone consults • KESHO secretariat/ Novartis (sponsorship) • Colleagues in Hemato-Oncology at KNH/UON